A B S T R A C T An abnormal fibrinogen (fibrinogen
INTRODUCTION
A number of hereditary abnormalities of fibrinogen (factor I) have been described in which the plasma of an individual contains normal amounts of qualitatively defective fibrinogen (1) .
Fibrinogen consists of three pairs of polypeptide chains, designated Aa, BP, and aY, joined at their NH2-terminal ends by disulfide bonds (2) . The conversion of plasma fibrinogen to fibrin clot takes place in three steps. First, thrombin selectively hydrolyzes an arginylglycine bond in each Aa and BPs chain, releasing fibrinopeptides A and B, respectively (2) . What remains, a so-called fibrin monomer, undergoes polymerization, forming a visible fibrin clot (3) . Finally, fibrin undergoes covalent cross-linking under the influence of fibrinstabilizing factor (factor XIII), resulting in a more stable clot, insoluble in dispersing agents (4) . Qualitative abnormalities of fibrinogen of each of the three steps of fibrin formation have been described. In the majority of cases studied, the site of the defect was localized to abnormal polymerization of fibrin monomers (1) . In at least five other families, the release of fibrinopeptides was abnormal (5) (6) (7) (8) (9) . One family has been described in which the fibrin of affected individuals was thought to respond defectively to the cross-linking action of fibrin-stabilizing factor (10) . The present report describes an apparently new Abnormal fibrinogen found in a 23-yr-old white man and in
The Journal of Clinical Investigation Volume 53 May 1974.1308-1319 1308 METHODS Plasma was prepared from venous blood, drawn in silicone-coated syringes from the proband, his relatives, and normal controls, mixed with 1/50 vol sodium citrate buffer (0.5 M, pH 5.0) and centrifuged at 2,200g for 15 min at 2°C.
The plasma was used fresh or stored in silicone-coated containers at -20°C or -70°C.
Fibrinogen fractions I-0, I-2, or I-4, prepared by techniques described by Blomback and Blomback (11) , were separated from normal or abnormal fresh or frozen plasmas.
Thrombin. Crude bovine thrombin (Topical Thrombin, Parke, Davis & Co., Detroit, Mich.) was dissolved in barbital-saline buffer at suitable concentrations. Purified thrombin was prepared by a method described earlier and dissolved in 0.05 M potassium phosphate buffer (pH 7.0) (12) . The preparation used had a specific activity of 1,150 NIH U/mg protein and was known to be contaminated with traces of Hageman factor (Factor XII) (13) .
Venoms. Reptilase, an extract of Bothrops jararaca venom, was a product of Pentapharm, Basel, Switzerland. Ancrod, the coagulant fraction of Ancistrodon rhodostoma (Venacil), was a gift of Abbott Laboratories, North Chicago, Ill. The procoagulant fraction of the venom of Ancistrodon contortrix contortrix, the southern copperhead snake, was separated from a crude preparation (Sigma Chemical Co., Inc., St. Louis, Mo.) as described previously (14) .
Other materials and procedures. Rabbit antiserum to human fibrin was obtained from Hyland Div., Travenol Laboratories, Inc., Costa Mesa, Calif. and used undiluted. Barbital-saline buffer was composed of 0.025 M sodium barbital and 0.125 M sodium chloride, at pH 7.4.
The whole blood clotting time was measured in 13 X 100-mm glass or 12 X 75-mm polystyrene tubes at 25°C, with fresh whole blood collected in silicone-coated syringes (15) . Clot retraction (16) and platelet counts (17) were performed on fresh whole blood; and the activated partial thromboplastin time, one-stage prothrombin time, serum prothrombin activity (prothrombin consumption), and plasma proaccelerin (factor V) and antihemophilic factor (factor VIII) activities were measured by previously referred-to methods (18) .
The concentration of plasma fibrinogen was measured on fresh or frozen plasmas by a modification (19) of an earlier method (20) . The coagulable fraction of fibrinogen preparations was determined by dividing the amount of fibrin that could be formed upon incubation with thrombin for 30 min at 37°C by the total protein content, determined in the same manner on the fibrinogen, solutions (20) .
Factor XIII activity was measured by incubating 0.2 ml plasma with 0.2 ml 0.025 M calcium chloride for 1 h at 37°C. 3 ml of 1% monochloroacetic acid was added, and the clots were incubated at room temperature for 24 h.
The protein content of the remaining fibrin clot was measured (19, 20) and compared with the plasma fibrinogen concentration.
The thrombin time was determined by measuring the clotting time at 37°C of a mixture of 0.2 ml of plasma or fibrinogen solution, pre-incubated for 1 min at 37°C, and 0.2 ml of crude bovine thrombin, diluted appropriately in barbital-saline buffer. In one experiment, 0.1 ml of 0.025 M calcium chloride solution was added just before the addition of thrombin. The effect of abnormal plasma upon the thrombin time was measured by adding 0.1 ml of abnormal or normal plasma to 0.1 ml of normal plasma. The mixtures were incubated for 1 min at 370C; 0.2 ml crude bovine thrombin (1.25 NIH U/ml) was added, and the clotting time measured at 370 C. The thrombin time of such mixtures was also measured in the presence of 0.1 ml of 0.025 M calcium chloride solution, added just before the addition of thrombin.
The effect of thrombinlike snake venoms was tested by an adaption of the thrombin time. The Reptilase time of whole plasma was assayed by measuring the clotting time at 370C of a mixture of 0.2 ml of plasma, incubated at 370C for 1 min, and 0.2 ml of Reptilase, diluted with an equal part of 0.025 M calcium chloride solution. The effect of venoms on purified fibrinogen (fraction I-2) was tested by incubating 0.2 ml of fibrinogen solution for 1 min at 370C, after which 0.1 ml of barbital-saline buffer or 0.025 M calcium chloride was added, followed immediately by 0.2 ml of ancrod, the procoagulant fraction of the southern copperhead snake venom, or Reptilase, and clotting time was measured at 370C. The fibrinogen solution contained 2.4 mg coagulable protein/ml; that prepared from normal plasma was 95%o coagulable, while that prepared from the proband was 92% coagulable.
All clotting times were measured in 10 X 75-mm disposable glass tubes.
Aggregation of platelets was measured at 370C in 1-ml samples of platelet-rich plasma (approximately 250, 000 platelets/mm8), with a Chrono-log platelet aggregometer (Chrono-log Corp., Broomall, Pa.) to measure the light transmittance through the mixture after the addition of 0.05 ml ADP, (Sigma Chemical Co.), 10 ug/ml, of barbitalsaline buffer or 0.1 ml bovine collagen, 0.7 mg protein/ ml of 0. (22) . The central well contained 0.01 ml undiluted rabbit anti-human fibrin antiserum, and the peripheral wells contained 0.01 ml of normal or abnormal plasma diluted with 2 vol of barbital-saline buffer, or 0.01 ml normal or abnormal fibrinogen (0.6 mg/ml of the same buffer). The gels were kept at room temperature for 24 h and then photographed.
Immunoelectrophoresis (23) of 0.004 ml of normal or abnormal plasma was carried out on a 1 X 3-in microscope slide in 0.9% agarose in 0.05 M sodium barbital buffer (pH 8.4) (26) .
Electron microscopy of fibrin was carried out by incubating normal or abnormal fibrinogen fraction I-2 (2.0 mg/ml barbital-saline buffer) with one equal volume of crude bovine thrombin (200 NIH U/ml) for 1 min for normal or 2 min for abnormal fibrinogen, at room temperature, directly on carbon-coated Formvar membranes (Belden Mfg. Co., Chicago, Ill.). At the end of the incubation time, the membranes were blotted with filter paper, washed twice with barbital-saline buffer, and then stained with 0.5% uranyl acetate, as described by Kay and Cuddigan (27) . The membranes were examined in an AEI EM-6B electron microscope (AEI Scientific Apparatus, Inc., Elmsford, N. Y.) at original magnifications of 10,000 and 80,000.
Total fibrinopeptide release was measured by a method adapted from that described by Sherman, Gaston, Kaplan, and Spivack (28) , in which the guanidino group of arginine is measured fluorometrically after the addition of aqueous ninhydrin at alkaline pH (29) . Arginine is COOH-terminal amino acid in both fibrinopeptides A and B; thus, its appearance in the supernatant fluid after clotting is a measure of release of the fibrinopeptides. Normal and ab1Abbreviations used in this paper: BAMe, benzoyl arginine methyl ester; EACA, epsilon aminocaproic acid; SDS, sodium dodecyl sulfate; TCA, trichloroacetic acid.
normal fibrinogen fractions I-0 (both 85-90% coagulable) were dissolved in barbital-saline buffer at a concentration of 3.3 mg coagulable protein/ml. Disodium EDTA and epsilon aminocaprois acid (EACA) were added at concentrations of 0.004 M and 0.005 M, respectively. 0.8 ml fibrinogen solution was placed in a series of 12 X 75-mm polystyrene tubes, and 0.1 ml distilled water was added to all except the internal standard tubes. At zero time, 0.1 ml purified bovine thrombin (2.5 NIH U/ml of barbital-saline buffer) was added to each tube except to the 0-min and internal standard samples. Samples were then incubated at 370C for 1-64 min, after which the reaction was stopped by the addition of 1.0 ml 15% trichloroacetic acid (TCA), and by shaking to disperse the clot. 1 ml of 15%o TCA was added to the 0-min sample and internal standard samples before the addition of thrombin. Finally, 0. Thus, an estimation of the quantity of fibrinopeptide present in solution could be made by this method. A comparison of the total fibrinopeptides released and fibrin clot formed was performed by a variation of this technique. Solutions of abnormal and normal fibrinogen fraction I-0 in barbital-saline buffer containing 0.005 M EACA and 0.025 M calcium chloride were incubated at 370C with purified bovine thrombin, at final concentrations of 1.25 or 10 NIH U/ml for various times, and total fibrinopeptide release was determined as described above. Duplicate tubes with 0.5 ml of the same mixtures were incubated at 370 C, the clot was removed at times corresponding to the incubation times of the fibrinopeptide release assay, and the protein content of the clot was measured (20) . Total fibrinopeptides released and the protein concentration of the fibrin clot were converted to moles (assuming fibrin mol wt = 330,000) and the ratio was determined.
Individual fibrinopeptide release was measured by incubating 2 ml (2 mg) of normal or abnormal fibrinogen in 0.008 M Tris buffer in 0.142 M sodium chloride solution (pH 7.4) and 0.5 mM disodium EDTA with 20 ,ul purified bovine thrombin of varying concentrations and for varying lengths of time. At the end of the desired incubation time, the clot was removed and dissolved in 1% monochloroacetic acid, and the protein content measured by spectrophotometry at 380 nm. 0.2 ml 30% TCA was added to the supernatant fluid to precipitate any remaining protein. The supernatant fluids were processed to remove the TCA and salt (30) and subjected to electrophoresis, and the fibrinopeptides were quantified as described previously (31) . This electrophoretic analysis also detected a fraction with the mobility of the tripeptide Gly-Pro-Arg with a precision no better than 30% (30) .
Fibrin monomer was prepared by incubating abnormal and normal fractions I-2 (92% and 95% coagulable, respectively), dissolved in 0.3 M HCI-Tris buffer (pH 7.4) with purified bovine thrombin (5.0 NIH U/ml) for (35) , was considered "fraction 1" (34) and discarded. The next 18%o of the protein eluate ("fraction 2"), which was believed to be rich in the dimeric NH2-terminal disulfide knot (34) was examined by electrophoresis in 7.5% polyacrylamide gel in 5% acetic acid (2, 36) and in 5%o polyacrylamide wl in SDS (2, 26) . To release fibrinopeptides for measurement, this fraction was first neutralized either by adding 1 M sodium carbonate or by lyophilizing and dissolving in 0.2 M ammonium bicarbonate at pH 8.2, and then was incubated in heavy-walled glass centrifuge tubes with purified thrombin at either 360 or 30 U/ml for periods of 2 and 18 h, respectively. The residual protein was precipitated by adding i vol of 50%o TCA, and fibrinopeptides in the supernatant fluid were determined as described above (30, 31) . (Table I ). The concentration of fibrinogen in the patient's plasma was normal, and fibrin-related antigens were not detected in his serum.
Family studies. In 16 of 24 tested relatives, the thrombin time and Reptilase time were prolonged and the levels of fibrinogen in their plasmas were normal. In all affected individuals, the prolonged thrombin times fell within 1 or 2 s of each other. Except for an uncle of the proband who bled after prostatectomy, all affected relatives were asymptomatic. The defect appeared to be inherited as an autosomal dominant trait; no consanguinity was known to the family (Fig. 1) .
Localization of the patient's defect to fibrinogen. The thrombin time of the patient's fibrinogen (fraction I-0) was prolonged, an abnormality partially corrected by the addition of calcium ions (Table II) . Similar results were obtained with the patient's fibrinogen fractions I-2 and I-4. When the patient's plasma was added to normal plasma, the thrombin time of the normal plasma became slightly prolonged. This inhibitory effect increased when an increased amount of patient's plasma was added, but was totally obliterated when calcium ions were added (Table III) .
The effect of snake venoms upon the coagulation of the abnormal fibrinogen was tested in an attempt to localize the abnormality. Ancrod and Reptilase selectively separate fibrinopeptide A from fibrinogen (37, 38) FIGURE 4 Total fibrinopeptide release from fibrinogen Cleveland II and normal fibrinogen. 2.6 ml of fibrinogen were incubated at 370C with thrombin (0.25 NIH U/ml).
The total fibrinopeptides released at various incubation times were measured by fluorescence of a mixture of the fibrinopeptides and alkaline ninhydrin, converted to micromoles and divided by 0.0076 smol (0.0076 uLmol = 2.6 mg fibrinogen) to determine moles fibrinopeptides per mole fibrinogen.
although more slowly than normal fibrinogen, but the copperhead procoagulant fraction was without discernible effect.
Immunologic studies of the abnormal fibrinogen. Abnormal plasma and purified fibrinogen formed a line of identity upon immunodiffusion against anti-fibrin antiserum. Upon immunoelectrophoresis, the abnormal fibrinogen migrated identically with normal fibrinogen toward the anode at pH 8.4 (Fig. 2) and toward the Chromatographic behavior of the abnormal fibrinogen. Upon chromatography on a column of DEAE cellulose, normal fibrinogen elutes in two major peaks (25) . The abnormal fibrinogen (fraction I-4) was eluted in two peaks in elution fractions with identical conductivity and pH as those elution fractions containing the same respective peaks of normal fibrinogen (fraction I-4). The coagulable protein was found in those fractions of eluate that contained antigens related to fibrin, as measured by gel diffusion. Electron microscopy of the abnormal fibrinogen. Fibrin clots from the abnormal fibrinogen examined by electron microscopy were found to have some unconnected strands that appeared to end abruptly, while in the normal fibrin network, almost all strands tapered gradually and were interconnected (Fig. 3, A and B) . Under greater magnification, the abnormal and normal fibrin strands had similar cross-banding of the same periodicity (220-230 A) (Fig. 3 C) .
Locus of the functional defect in the abnormal fibrinogen. The locus of the functional defect in the abnormal fibrinogen was determined by examining each step of the fibrinogen-to-fibrin conversion process separately.
In repeated experiments, the release of total fibrinopeptides from the abnormal fibrinogen was slower than from normal fibrinogen when both were incubated with thrombin (0.25 NIH U/ml) (Fig. 4) abnormal fibrinogen was incubated with thrombin, the rate of release of fibrinopeptide B fell only slightly below normal (Fig. 5) , whereas the release of fibrinopeptide A was significantly retarded (Fig. 6) . After prolonged incubation, yields of fibrinopeptide B reached the same level as normal, but fibrinopeptide A consistently fell short of normal by 35-55%, regardless of thrombin concentration, spanning 3-30 U/ml (Table  VI) . These experiments were carried out in the presence of EDTA, and there was incomplete incorporation of abnormal fibrinogen into fibrin clot. In most experiments, however, less than the expected 2 nmol of fibrinopeptide A were released for each nmol of fibrin clot formed from the abnormal fibrinogen.
The method of preparation of fibrin monomers (soluble fibrin) allowed maximum release of those fibrinopeptides that could be separated from the normal or abnormal fibrinogen. The fibrin monomers showed no evidence of cross-linking by SDS gel electrophoresis of the reduced proteins (32) . When SDS. The relative migration of the polypeptide chains has been published elsewhere (32) . After incubation of both the normal and abnormal fibrinogen with thrombin (2.0 NIH U/ml) for 1 min some y-y dimers had formed; after 15 min incubation, 'y-y dimer formation was almost complete in both. No free -r chains were apparent after incubation for 30 (Fig. 8) . Thus, the abnormal fibrin was cross-linked at a slower rate than normal fibrin but eventually it appeared to be cross-linked to the same degree as normal fibrin.
Fraction 2 of CNBr-treated normal fibrinogen and fibrinogen Cleveland II were characterized by electrophoresis in polyacrylamide gel in 5% acetic acid (36) and in SDS (26) (33) , was slower in the abnormal fibrin preparation, but the degree of aggregation ultimately achieved was similar to that of normal fibrin (Fig. 7) . The abnormal fibrinogen demonstrated a partial correction of the thrombin time by the addition of calcium ions and the property of being mildly inhibitory to clotting of normal fibrinogen by thrombin. Fibrinogen Cleveland II, however, was indistinguishable from normal fibrinogen by immunoelectrophoresis, DEAE-cellulose column chromatography, or polyacrylamide gel electrophoresis of reduced fibrinogen in SDS.
Functionally, the major defect discerned in the abnormal fibrinogen was impaired release of fibrinopeptide A upon incubation with thrombin. The release of fibrinopeptide A occurred more slowly than normally, and the total amount of this peptide released was less than the expected amount. Under the experimental conditions used, the total release of fibrinopeptide A was not observed.
In addition to, and perhaps as a result of, the defect in fibrinopeptide release, the abnormal fibrinogen demonstrated a slower than normal polymerization of its fibrin monomers at pH 7.4.
Finally, the abnormal fibrin demonstrated a decrease in the rate of progress of cross-linking, but the degree of cross-linking eventually achieved appeared to be the same as normal fibrin.
Despite these defective steps in the fibrinogen-to-fibrin clot conversion, under some conditions the abnormal fibrinogen demonstrated a degree of coagulability similar to that of normal fibrinogen. This was shown by three separate observations. In the absence of EDTA, purified preparations of abnormal and normal fibrinogens exhibited a similar degree of coagulability, while the abnormal fibrinogen retained its prolonged thrombin time. Polyacrylamide gel electrophoresis of reduced fibrin, which demonstrated the progress of cross-linking, showed no free v chain after prolonged incubation. One would anticipate that free yr chains would be observed if some fibrinogen molecules remained disassociated from the fibrin clot. Thirdly, there was no fibrin-related antigen in the proband's serum. Thus, after clotting, it appeared that all the fibrinogen-related antigen had been incorporated into the clot.
Since fibrinogen Cleveland II demonstrated a degree of coagulability similar to normal fibrinogen, yet under no conditions was it observed to release all of its fibrinopeptide A, it seemed likely that some fibrin molecules with fibrinopeptide A still intact were incorporated into the fibrin clot. This notion was further supported by the consistent observation that, upon incubation of fibrinogen Cleveland II with thrombin in the presence of calcium ion, about 3 mol of fibrinopeptides was released per 1 mol of fibrin formed. Under the same conditions, normal fibrinogen released about 4 mol of fibrinopeptides per 1 mol of fibrin formed. In experiments in which individual fibrinopeptides were measured, incomplete coagulability of fibrinogen Cleveland II was noted. These experiments were performed in the presence of EDTA, which may account for this observation, since EDTA makes conditions for polymerization of fibrin monomers less favorable (40) . Nevertheless, in most of these experiments, less than 2 nmol of fibrinopeptide A were released for each nmol of fibrin clot formed, implying that some fibrin molecules in the formed clot had not released all of its fibrinopeptide A.
Thus it appeared that in this abnormal fibrinogen, complete release of fibrinopeptide A from the fibrinogen was not necessary for its conversion to cross-linked fibrin by thrombin. The process was slower than normal, however, and electron microscopic study of the fibrin suggested that it was not entirely structurally normal.
The exact site of the defect in the patient's fibrinogen was no determined. Studies of the NH-terminal disulfide knot (i.e., the portion of the fibrinogen molecule containing the fibrinopeptides) however, demonstrated that the defect was within this region.
Since the affected individuals with fibrinogen Cleveland II released about one-half the expected amount of fibrinopeptide A and since this defect appeared to be transmitted as an autosomal dominant trait, it was probable that the affected individuals were heterozygous for defective fibrinopeptide A release. Whether this was a result of two species of one of the polypeptide chains, one normal and one abnormal, making up the fibrinogen molecule or two species of fibrinogen, one normal and one abnormal, could not be determined. However, two species of fibrinogen, presumably one normal and one abnormal, have been detected in the plasmas of affected individuals with some other abnormal fibrinogens (fibrinogen Baltimore [41] , Cleveland I [18] , Bethesda I [6] , Zurich I [42] and Los Angeles [43] ).
Fibrinogen Cleveland II is most likely a new form of inherited abnormal fibrinogen. At least five families have been described in which an abnormal fibrinogen demonstrated an abnormality in fibrinopeptide release. In fibrinogen Baltimore there was a slower than normal release of fibrinopeptide A, but upon prolonged incubation all of the fibrinopeptide A was released (5) . In fibrinogen Detroit the release of fibrinopeptide A was apparently normal, but the fibrinopeptide B was not released (7) . In fibrinogen Bethesda I both fibrinopeptides A and B were released abnormally slowly, but if incubation with thrombin was prolonged, total release finally occurred (6) . Functionally, fibrinogen Cleveland II closely resembled fibrinogens Geissen (9) and Metz (8) . Fibrinogen Geissen did not release its fibrinopeptide A (44), while fibrinogen Metz had a defect in total fibrinopeptide release; presumably this defect represented failure to release the fibrinopeptide A since there was no fibrinopeptide release with Reptilase (8) . Both fibrinogens Geissen (45) and Metz (8) as well as fibrinogens Baltimore (46) and Bethesda I (6) had a mobility on immunoelectrophoresis that was different from normal fibrinogen, unlike fibrinogen Cleveland II.
By virtue-of the demonstration of abnormal fibrinopeptide release, fibrinogen Cleveland II 
